RenovoRX
  • Media
  • Careers
  • Investors
  • About
    • Leadership Team
    • Board of Directors
    • Advisory Board
  • Clinical Trials
    • About TIGeR-PaC
    • TIGeR-PaC
      Candidate Criteria
    • TIGeR-PaC Participating
      Clinical Sites
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • Contact
  • About
    • Leadership Team
    • Board of Directors
    • Advisory Board
  • Clinical Trials
    • About TIGeR-PaC
    • TIGeR-PaC
      Candidate Criteria
    • TIGeR-PaC Participating
      Clinical Sites
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • News
  • Careers
  • Investors
  • Contact
Investors

Investors

  • Overview
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • News & Events
    • Overview
    • Press Releases
    • Clinical News
    • IR Calendar Events
    • Email Alerts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Clinical News
  • IR Calendar Events
  • Email Alerts
Mar 02, 2023 8:30am EST

RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone

Mar 01, 2023 8:30am EST

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

Jan 25, 2023 8:30am EST

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

Jan 18, 2023 8:30am EST

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

Jan 05, 2023 8:30am EST

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

Dec 15, 2022 8:30am EST

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

Nov 17, 2022 8:30am EST

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

Nov 14, 2022 8:30am EST

RenovoRx Reports Third Quarter 2022 Financial Results

Oct 21, 2022 8:30am EDT

RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET

Oct 04, 2022 8:00am EDT

RenovoRx to Participate in Upcoming October 2022 Investor Conferences

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

2570 W. El Camino Real, Suite 320
Mountain View, CA 94040

(650) 284-4433

(650) 397-4433

RenovoRX

Delivering Therapy Where it Matters

Quicklinks
  • About
  • Clinical Trials
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • Media
  • Careers
  • Investors
  • Contact

Delivering Therapy Where it Matters

4546 El Camino Real, Suite B1
Los Altos, CA 94022

(650) 284-4433

(650) 397-4433

Quicklinks
  • About
  • Clinical Trials
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • News
  • Careers
  • Investors
  • Contact

© Copyright 2018-2025 RenovoRx®. All rights reserved. Site by Sheriar Designs.

Privacy Statement | Terms of Use

Menu